The Oncology Institute, Inc. (TOI)
NASDAQ: TOI · Real-Time Price · USD
3.490
+0.080 (2.35%)
Jul 22, 2025, 2:17 PM - Market open

Company Description

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States.

The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other.

It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance services.

The company also provides and manages clinical trials, palliative care programs, stem cell transplants services, other care delivery models associated with non-community-based academic, and tertiary care settings; and conducts clinical trials for a range of pharmaceutical, and medical device companies.

It serves adult and senior cancer patients. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

The Oncology Institute, Inc.
The Oncology Institute logo
CountryUnited States
Founded2007
IndustryMedical Care Facilities
SectorHealthcare
Employees825
CEODaniel Virnich

Contact Details

Address:
18000 Studebaker Road, Suite 800
Cerritos, California 90703
United States
Phone562 735 3226
Websitetheoncologyinstitute.com

Stock Details

Ticker SymbolTOI
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001799191
CUSIP Number68236X100
ISIN NumberUS68236X1000
Employer ID84-3562323
SIC Code8011

Key Executives

NamePosition
Dr. Daniel Virnich FACHE, M.B.A., M.D.Chief Executive Officer and Executive Director
Richard Alan BaraschChairman of the Board
Dr. Yale D. Podnos F.A.C.S., M.D., M.P.H.Chief Medical Officer
Robert CarterChief Financial Officer
Austin LeeVice President of Accounting and Controller
Mark Hueppelsheuser Esq.General Counsel
Jordan McInerneyChief Development Officer
Stephen CellaSenior Vice President of Finance
Dr. Jeffrey Langsam M.D.Chief Clinical Officer

Latest SEC Filings

DateTypeTitle
Jun 24, 2025SCHEDULE 13G/AFiling
Jun 18, 2025EFFECTNotice of Effectiveness
Jun 16, 2025S-3/A[Amend] Registration statement under Securities Act of 1933
Jun 12, 2025UPLOADFiling
Jun 6, 2025S-3Registration statement under Securities Act of 1933
Jun 5, 2025144Filing
Jun 5, 2025144Filing
Jun 3, 2025144Filing
Jun 3, 2025144Filing
May 20, 2025144Filing